Abstract 53P
Background
Glioblastoma is the one of most fast-growing primary brain tumor in adult and it carries the worst prognosis. Atorvastatin is an inhibitor of HMG-CoA reductase, a rate-limiting enzyme in the mevalonate pathway. Preclinical studies demonstrate encouraging anticancer activity of statins. The primary objective of the study was to evaluate the efficacy of Atorvastatin in addition to the standard therapy in patients with glioblastoma.
Methods
In this open-label, prospective, single-arm, phase II study, eligible patients received Atorvastatin in combination with standard therapy comprising radiotherapy and Temozolomide (TMZ). The primary endpoint is progression free survival (PFS) at 6 months. A minimum of 80% power required at least 32 eligible patients with planned final analysis after at least 1 year from last recruited patient.
Results
From January 2014 to December 2016, 36 evaluable patients were enrolled. Median age was 52 (20-69); 22% were ≥ 60 years of age and 62% were male. 97% of patients underwent resection. All patients have received Atorvastatin for a median of 6.2 (0.3 – 28 ) months duration, 80% of patients have discontinued this because of disease progression. At a median follow-up of 19 months, PFS-6 rate was 66% with median PFS of 7.6 months. Median overall survival was 19.9 months (4.8 – 42.5 months). Grades 3 and 4 hematological adverse events, including neutropenia and thrombocytopenia occurred in 7% and 12 % of patients respectively. On multivariate analysis, worse survival was associated in patients with baseline high LDL level (p = 0.046) and better survival was seen in patients received adjuvant TMZ (p = 0.001) and methylated tumors (p = 0.013).
Conclusions
This study did not meet its primary endpoint of PFS-6 compared to historical controls. However, this study proves the fact that high LDL level was found to be an important independent predictor of poor cancer-related outcome. Future clinical trials testing statins should aim to enroll patients with slow-growing tumors.
Clinical trial identification
clinical trial information: NCT02029573.
Editorial acknowledgement
Legal entity responsible for the study
King Fahad Medical City.
Funding
King Fahad Medical City.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract